TPST (Tempest Therapeutics) Selling and Marketing Expense: $ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPST Tempest Therapeutics Inc TPST
30 GF Score
Price $0.77
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Selling and Marketing Expense?

Tempest Therapeutics TPST -20.52% 30 Selling and Marketing Expense is $ Mil as of Jun. 2026. GuruFocus rates TPST with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Tempest Therapeutics's Selling and Marketing Expense for the three months ended in Jun. 2026 was $ Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2026 was $ Mil.

Tempest Therapeutics Selling and Marketing Expense Related Terms

Tempest Therapeutics Selling and Marketing Expense Historical Data

* Premium members only.

The historical data trend for Tempest Therapeutics's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics Selling and Marketing Expense Chart

Tempest Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tempest Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
TPST
30GF Score
Tempest Therapeutics Inc TPST
Selling and Marketing Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling and Marketing Expense of $ Mil mean?
Tempest Therapeutics (TPST) has a Selling and Marketing Expense of $ Mil as of Jun. 2026. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on Tempest Therapeutics and its competitors.
Is Tempest Therapeutics' Selling and Marketing Expense too high?
Tempest Therapeutics' current Selling and Marketing Expense is $ Mil. Overall, Tempest Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Selling and Marketing Expense compare to LPCN and CYCN?
Tempest Therapeutics' Selling and Marketing Expense of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling and Marketing Expense for a Biotechnology company?
A good Selling and Marketing Expense depends on the Biotechnology industry context. However, Selling and Marketing Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling and Marketing Expense mean?
A high Selling and Marketing Expense can signal that a stock is expensive relative to its fundamentals. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on Tempest Therapeutics and its competitors. Tempest Therapeutics's current Selling and Marketing Expense is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current Selling and Marketing Expense of $ Mil. The current Selling and Marketing Expense is $ Mil. Tempest Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling and Marketing Expense calculated?
Selling and Marketing Expense is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current Selling and Marketing Expense is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
30GF Score

Get the complete analysis for TPST

Selling and Marketing Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.77
Price